Pharmacogenetic Variation Of CYP2C19 Affecting The Efficacy Of Anti-Platelet Therapy
Main Article Content
Abstract
Antiplatelet drugs used to treat and prevent platelet aggregation in conditions like stroke and cardiovascular events. Pharmacogenetics plays a vital role in affecting the treatment outcome due to its variation. Cytochrome P450 (CYP450) enzymes especially, CYP2C19 play in the metabolism of a variety of medications, including clopidogrel and genetic variation of CYP2C19 may affect clopidogrel metabolism which is a prodrug. Through encouraging a shift in antiplatelet therapy toward customized medicine, it improves the science of pharmacogenetics. More precise and effective patient care in the area of cardiovascular health is possible if doctors are encouraged to consider hereditary traits while prescribing antiplatelet medications.
Keywords: Anti-platelet, pharmacogenetics, CYP450, genetic variation in CYP2C19, clopidogrel, prasugrel and ticagrelor
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Eikelboom JW, Hirsh J, Spencer FA, Baglin TP, Weitz JI. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012 Feb; 41(2 Suppl):e89S-e119S.
Overcoming limitations of current antiplatelet drugs: a concerted effort for more profitable strategies of intervention - PubMed [Internet]. [cited 2024 Jan 9]. Available from:
https://pubmed.ncbi.nlm.nih.gov/21815879/
Varga-Szabo D, Pleines I, Nieswandt B. Cell adhesion mechanisms in platelets. Arterioscler Thromb Vasc Biol. 2008 Mar; 28(3):403–12.
Raymenants E, Yang B, Nicolini F, Behrens P, Lawson D, Mehta JL. Verapamil and aspirin modulate platelet-mediated vasomotion in arterial segments with intact or disrupted endothelium. J Am Coll Cardiol. 1993 Sep; 22(3):684–9.
Beynon C, Hertle DN, Unterberg AW, Sakowitz OW. Clinical review: Traumatic brain injury in patients receiving antiplatelet medication. Crit Care Lond Engl. 2012 Jul 26;16(4):228.
Jeffrey R. Bishop, in Handbook of Clinical Neurology, 2018.
Lanham KJ, Oestreich JH, Dunn SP, Steinhubl SR. Impact of genetic polymorphisms on clinical response to antithrombotics. Pharmacogenomics Pers Med. 2010;3:87–99.
Shimada T, Yamazaki H, Mimura M, Wakamiya N, Ueng YF, Guengerich FP, et al. Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. Drug Metab Dispos Biol Fate Chem. 1996 May;24(5):515–22.
Padmanabhan, S. (Ed.). (2014). Handbook of pharmacogenomics and stratified medicine. Academic Press.
Brown SA, Pereira N. Pharmacogenomic Impact of CYP2C19 Variation on Clopidogrel Therapy in Precision Cardiovascular Medicine. J Pers Med. 2018 Jan 30;8(1):8.
Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P- 450 Polymorphisms and Response to Clopidogrel. N Engl J Med. 2009 Jan22;360(4):354– 62.
Sibbing D, Gebhard D, Koch W, Braun S, Stegherr J, Morath T, et al. Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy. J Thromb Haemost JTH. 2010 Aug;8(8):1685–93.
Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med. 2009 Jan 22;360(4):363–75.
Sibbing D, Stegherr J, Latz W, Koch W, Mehilli J, Dörrler K, et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J. 2009 Apr;30(8):916–22.
Chen H, Yan W, Wu X ying. [Relationships of blood stasis syndrome, CYP2C19 gene polymorphism with clopidogrel resistance and post-PCI prognosis]. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi Chin J Integr Tradit West Med [Internet]. 2010 Dec 1 [cited 2024 Jan 9]; Available from:
https://www.semanticscholar.org/paper/%5BRelationships-of-blood-stasis- syndrome%2C- CYP2C19-Chen-Yan/ccd318dc5f634e283dc9454092d6533b107c5906
Angiolillo DJ, Shoemaker SB, Desai B, Yuan H, Charlton RK, Bernardo E, et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation. 2007 Feb 13;115(6):708–16.
Mega JL, Hochholzer W, Frelinger AL, Kluk MJ, Angiolillo DJ, Kereiakes DJ, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA. 2011 Nov 23;306(20):2221–8.
Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, et al. Influence of Genetic Polymorphisms on the Effect of High- and Standard-Dose Clopidogrel After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2012 May;59(22):1928–37.
Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013 Sep;94(3):317–23.
Song PS, Hahn JY, Song YB, Choi JH, Choi SH, Kang GH, et al. Effects of 600 mg versus 300 mg Loading Dose of Clopidogrel in Asian Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Long-Term Follow-Up Study. Yonsei Med J. 2012 Sep 9;53(5):906.
Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10;361(11):1045–57.
Chen H. Integrative Medicine on Optimizing Clopidogrel and Aspirin Therapy. Chin J Integr Med. 2019 May 1;25(5):395–400.